Abstract. Malignant B cells in chronic lymphocytic leukemia serve an essential role in the whole immune response, so their interactions with other immune cells are more complex than observed in solid tumors. The latest study results indicate that the immune dysregulation in chronic lymphocytic leukemia (CLL) also affects a small population of invariant natural killer T cells (iNKT). Using peripheral blood iNKT cells obtained from patients with CLL, the objective of the present study was to assess the intracellular expression of typical cytokines involved in the Th1 (IFN-γ) and Th2 (IL-4) response pathways following stimulation with the iNKT-specific ligand α-galactosylceramide. iNKT cells from patients with CLL exhibited upregulated IL-4 and IFN-γ expression in comparison to those from HVs. No significant association between the ability of iNKT cells to produce IL-4 or IFN-γ and the expression of CD1d on leukemic B lymphocytes or monocytes was identified. However, the function of iNKT cells was compromised in patients with CLL by a strong Th2 bias (high IL-4 and low IFN-γ expression). The ratio of iNKT + was significantly decreased in the CLL group when compared with HVs, and this decreased further as the disease progressed. This change may result in the promotion of leukemic B lymphocyte survival. Therefore, in the pathogenesis of CLL, Th2 bias may delay the antitumor response that relies on stimulation of the Th1 immune response.
Introduction
In chronic lymphocytic leukemia (CLL), malignant B lymphocytes, similar to other tumor cells, are in constant cooperation with the tumor microenvironment, which is formed by cancer cells through the recruitment and alteration of non-malignant cells of the immune system (1) . In their proximate surroundings, neoplastic B cells interact with neighboring cells that include mesenchymal stromal cells, monocytes, monocyte-derived nurse-like cells, and T cells (2) . These interactions provide B cell clones with supporting factors that inhibit or delay programmed apoptosis and thereby sustain disease progression (3) . The dialogue between CLL B cells and interacting T lymphocytes may involve cytokines (4) . The present study focused on a population of T lymphocytes, known as invariant natural killer T cells (iNKT) (5) . The role of iNKT in tumor immunity is only partially understood and is poorly described in CLL. This unique cell subset combines features of T lymphocytes and NK cells (6) . Unlike conventional T lymphocytes, they express markedly less variable T cell receptors (TCRαβ), and are formed by an invariant α chain (Vα24Jα18) combined with a limited set of β chains, mainly containing Vβ11 (7) (8) (9) . Using such TCR receptors, iNKT cells recognize lipids and glycolipids, presented by a non-classical MHC molecule known as CD1d (10) . The agent most efficient in binding to CD1d is a synthetic compound that originated from marine sponges, known as α-galactosylceramide (α-GalCer). The discovery of this potent agonist facilitated further understanding of the biology of iNKT (11) (12) (13) . Activated iNKT cells simultaneously secrete interferon (IFN)-γ and interleukin (IL)-4 (14) . In addition, they can release other pro-inflammatory Th1 cytokines [such as tumor necrosis factor (TNF)-α and IL -6] and anti-inflammatory Th2 cytokines [such as IL-10, IL-13 and transforming growth factor (TGF)-β] (14) (15) (16) . This enables iNKT cells to influence other cells of the immune system, including NK cells, cytotoxic T lymphocytes, helper T cells, B cells and antigen presenting cells (APC) (17) (18) (19) . Certain pathological conditions may cause a change in the Th0-like pattern of cytokines secreted by iNKT cells and polarize their response in the Th1 or Th2 direction (10, 20) . Such iNKT cells can modify the microenvironment and influence tumor control (21) . The role of these cells in the pathogenesis and clinical course of CLL is not well known. Understanding the function of iNKT cells in this specific type of leukemia requires critical analysis of the cytokine release profile. In the current study, the intracellular expression of IFN-γ and IL-4 was analyzed by stimulating the iNKT cells. (Fig. 1A) . iNKT cells were defined and gated on a dot plot of iNKT FITC (TCR Vα24-Jα18) vs. CD3 PE-Cy5 (Fig. 1B) . Within those cells, the cytokine expressing cells were identified. To establish the gating strategy, a fluorescence minus one (FMO) control was used. The FMO control tube included all antibodies that were used for iNKT cell staining 
Materials and methods

Patients
Sorting of iNKT cells for reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
In 10 CLL cases and 5 HV cases (from 24-h culture with and without α-GalCer stimulation), the iNKT cells were purified. A BD FACSAria™ flow cytometer (BD Biosciences) was used for iNKT cell sorting. In this case, the iNKT cells were labeled with antibodies against TCR, Vα24-Jα18 PE and CD3 FITC (BD Biosciences), following which the double-positive population was selected. A standard whole-blood assay with erythrocyte cell lysis was used for preparing the PB specimens. After sorting, the iNKT cell purity was >97%.
RNA preparation and RT-qPCR) for IL-4 and IFN-γ in iNKT cells.
Purified iNKT cells were used for RNA isolation. Total RNA was isolated using the QIAamp ® RNA Blood Mini kit (Qiagen, Inc., Valencia, CA, USA; cat. no. 52304). RNA was transcribed into cDNA using the QuantiTect ® Reverse Transcription kit (Qiagen, Inc.; cat. no. 205311), according to the manufacturer's protocol. RT-qPCR was performed using TaqMan reagents specific for human IL-4 and IFN-γ (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA; cat. no. 4331182), and β-actin was used as the internal control (Applied Biosystems; Thermo Fisher Scientific, Inc.; cat. no. 4326315E). RT-qPCR reactions were run for 40 cycles using universal cycling conditions (95˚C for 10 min followed by 40 cycles at 95˚C for 15 sec and 60˚C for 1 min) on an Applied Biosystems 7300 Real-Time PCR System. Data were normalized to β-actin expression (endogenous control), analyzed using the threshold cycle (Cq) and presented as 2 ΔCq . ΔCq is the difference between the Cq of the target gene (Cq t ) and the reference gene (Cq r ; DCq = Cq t -Cq r ) (24) .
Analysis of CD1d expression on monocytes and B cells. Flow cytometry analysis of CD19
+ B cells and CD14 + monocytes expressing CD1d was performed on fresh PB samples stained with anti-CD1d PE (clone CD1d42; cat. no. 550255, 20 µl/test), anti-CD19 FITC (clone SJ25C1; cat. no. 34040, 20 µl/test, 6 µg/ml) and anti-CD14 FITC (clone MφP9; cat. no. 347493; 20 µl/test, 25 µg/ml) MoAbs from BD Biosciences. Cells were incubated for 20 min at room temperature. A standard whole-blood assay with erythrocyte cell lysis was used for preparing all PB specimens. Samples were analyzed by flow cytometry directly following preparation. In the experiment, the percentage of CD1d + /CD19 + and CD1d + /CD14 + cells, and the level of CD1d expression on monocytes and B cells, indicated by the mean fluorescence intensity (MFI), were analyzed. Dot plots illustrating the analysis method for the identification of monocytes with membrane expression of CD1d are presented in Fig. 2 . The identification method of CD1d-positive CD19 + B lymphocytes was exhibited in our previous study (25) .
Cells isolation for the determination of apoptosis.
Mononuclear cells were separated from PB samples by density gradient centrifugation with Biocoll Separating Solution (Biochrom, Ltd., Cambridge, UK) for 25 min at 400 x g and room temperature. Interphase cells were removed, washed twice and resuspended in PBS.
Determination of apoptosis by MitoTracker
® Red CMXRos. In 20 patients with CLL an apoptosis analysis within the CD19 + cell population was performed. A previously described method was used for flow cytometric examination of the percentage of early apoptotic cells (ΔΨm low ) (26) (27) (28) after 24 h incubation at 37˚C in RPMI-1640 supplemented with 2 mmol/l L-glutamine (Biochrom, Ltd., Cambridge, UK; cat. no. FG1215), 10% fetal calf serum (Biochrom, Ltd.; cat. no. S0113), 100 U/ml penicillin and 100 µg/ml streptomycin (Biochrom, Ltd.; cat. no. A2212), and with and without 100 ng/ml α-GalCer stimulation. Statistical analysis. Data are presented as the median and range. The Mann-Whitney U test was applied for statistical comparisons between the CLL and HV groups, as well as between the patient subgroups. The Spearman's rank correlation coefficient was used for correlation analysis. Statistica version 9.0 PL software (StatSoft, Cracow, Poland) and GraphPad Prism software version 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) were used for statistical procedures. P<0.05 was considered to indicate a statistically significant difference.
Analysis of CD69 expression on iNKT cells.
Results
Intracellular IL-4 and IFN-γ expression in iNKT cells. The percentage of iNKT cells within CD3
+ T lymphocytes was significantly decreased in patients with CLL in comparison to the HVs (median, 0.21 vs. 0.42%, P<0.01; Fig. 3A) . The frequency of iNKT cells also decreased with the disease stage. The median percentage of iNKT cells in stage 0 was 0.25, 0.21% in stages I/II and 0.13% in stages III/IV, according to the Rai classification. However, the difference was not significant. In the group of patients with CLL no significant association was identified between the frequency of iNKT cells in the PB and the expression of ZAP-70 or CD38 (data not presented).
The function of iNKT lymphocytes was investigated through the analysis of intracellular cytokine expression following stimulation with the iNKT-specific ligand α-GalCer. At the end of a 24-h stimulation period, the synthesis of IL-4 and IFN-γ in iNKT cells was assessed by intracellular staining. In patients with CLL as well as in HVs, the percentage of iNKT cells with intracellular IL-4 or IFN-γ expression in non-activation assays was frequently <1%, comparable with the level of auto-fluorescence (Fig. 1G-H) . In vitro stimulation of iNKT cells with α-GalCer resulted in CD69 upregulation, indicating the activation of iNKT cells (median of iNKT + CD69 + cells, 15.79% before and 29.32% after α-GalCer). Higher percentages of iNKT with IL-4 expression were noted in patients with + cells in comparison with the HVs. However, there was no significant difference between the three risk groups (Fig. 5A) . Furthermore, each risk group exhibited a significantly higher percentage of iNKT + IFN-γ + cells in comparison with the control group (Fig. 5B) . However, when the risk groups were compared, the only significant finding was that patients with CLL at Rai stage III-IV had a lower percentage of iNKT (Fig. 5C) .
The proportions of CLL group iNKT differed slightly in the intracellular expression of cytokines, depending on the ZAP-70 factor expression. The percentage of iNKT cells expressing IL-4 was increased in ZAP-70-positive patients, as compared with in ZAP-70-negative patients (Table II) . Additionally, a tendency towards an increased percentage of iNKT cells expressing IL-4 in CD38-positive in comparison with CD38-negative patients was noted, but this difference was not statistically significant (Table II) (R=0.358; P<0.05) and β 2 -microglobulin levels (R=0.474; P<0.01). There was also an inverse correlation between the iNKT + IFN-γ + : iNKT + IL-4 + ratio and the WBC count (R=-0.302; P<0.05) and β 2 -microglobulin levels (R=0.507; P<0.01). However, no significant association between the percentage of iNKT + IFN-γ + cells and other disease parameters was identified.
In the present study, PB samples were obtained from untreated patients with CLL diagnosed between September 2014 and June 2016 (21 months of observations). During the follow-up period, the treatment was initiated in 12 patients (20%). For these patients, the median time to treatment (TTT) was 7 months (range, 0-12 months). TTT was defined as the interval from the date of diagnosis to the date of first treatment. There was no significant association between the percentage of iNKT (Table III) .
Expression of IL-4 and IFN-γ mRNAs in iNKT cells.
Purified iNKT cells were analyzed for IL-4 and IFN-γ mRNA expression using RT-qPCR. For the analysis of IL-4 and IFN-γ mRNA expression, each sample was normalized to β-actin. Generally, after 24 h of culture without stimulation, no IL-4 or IFN-γ mRNA was identified in the iNKT cells from patients with CLL or from the HVs. Only in one patient (p#5) was the presence of IL-4 and IFN-γ mRNA in an unstimulated culture observed (Fig. 6) . iNKT cells from patients with CLL and HVs were identified to express IL-4 (median 2 
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Membrane CD1d expression on B cells and monocytes from
patients with CLL and HVs. Our previous data (25) indicated that the median percentage of CD1d-positive B cells in patients with CLL was significantly lower than in HVs. Similarly, when the level of membrane CD1d expression determined by MFI on B cells was compared between patients with CLL and HVs, we identified a significant difference between the groups. In the present study, our previous results (25) that the percentage of B cells CD1d+ in CLL patients was significantly lower than in HVs were confirmed. Furthermore, in the current study, CD1d expression was detected on monocytes. Fig. 2 presents two representative types of monocytes with CD1d expression for patients with CLL (CLL1-CLL2), and two representative types of CD1d-positive monocytes for HVs (HV1-HV2). The percentage of monocytes with CD1d expression was significantly lower in patients with CLL in comparison with the HVs (median, 85.73%; range, 65.78-99.15% vs. median, 92.86%; range, 88.55-99.89%; P<0.05). Similarly, the level of membrane CD1d expression determined by MFI on monocytes was reduced in patients with CLL (median 182.60 MFI in HVs; 161.40 MFI in the CLL group). However, this difference was not statistically significant. Furthermore, no significant association between the expression levels of IL-4 or IFN-γ in iNKT cells and CD1d expression on leukemic B lymphocytes or monocytes from patients with CLL was identified. + lymphocytes in 24 h in vitro culture (P<0.05). However, there was no significant difference in the percentage of apoptotic CD19
Apoptosis
+ lymphocytes between the cultures with and without α-GalCer (Table IV) 
Discussion
Deficiencies in cytokine production by the T-lymphocytes of patients with CLL have previously been noted in certain studies (29, 30) , but few concentrated on the small but essential T cell subpopulation of iNKT (31) . iNKT cells recognize lipid antigens, such as α GalCer, when presented in a complex with CD1d (32) . To evaluate the functionality of iNKT lymphocytes, they were cultured in vitro and stimulated with the iNKT-specific ligand α-GalCer. It is challenging to select suitable stimulation methods for the analysis of cytokine production, especially for rare cell populations (e.g., iNKT cells). In the present study, whole blood samples were stimulated in vitro. Analysis of cytokine synthesis in whole blood has been utilized in previous studies (33) (34) (35) . Such a method may imitate the natural in vivo environment (34) . It was identified that α-GalCer stimulation induced a stronger intracellular cytokine response in patients with CLL, when compared with HVs. Following culture with α-GalCer, iNKT cells exhibited upregulated expression of CD69, an early activation marker, indicating that the examined cells retained the ability to respond to stimulation. In patients with CLL, the percentage of iNKT Changes in T cell cytokine secretion profile, associated with a Th2 shift, were described for advanced CLL cases (30). Hill et al (36) reported a reduction in IFN-γ and IL-4 expression by CD4 + T cells from patients with CLL. However, little data concerning cytokine production by iNKT cells have previously been presented. Weinkove et al (31) analyzed the cytokine profile and the proliferative capacity of circulating iNKT cells from patients with CLL. These authors observed an increased tendency towards an iNKT CD4 + subset (characterized by a production of Th2 cytokines) and a reduced tendency towards an iNKT CD8 + subset, although the results were not statistically significant. A comparison of patients with CLL and HVs revealed a lack of functional differences in, and no difference in the numbers of, iNKT cells; the cytokine production and in vitro proliferation of iNKT were similar. In the study, the authors evaluated a population of iNKT cells obtained from patients primarily in the early stages of the disease (31) . It was suggested that the analysis of iNKT cells from patients with advanced-stage CLL could provide more diverse results. In the present study, no significant differences were observed in the percentage of iNKT + ratio and the WBC count, as well as the β 2 -microglobulin levels. Furthermore, the ratio was lower in advanced-stages compared with the early stages of the disease, and was lower in ZAP-70-positive patients. Similarly, a tendency towards the reduction in the ratio of iNKT + IFN-γ + to iNKT + IL-4 + was observed in patients with CLL who also had del (11q22.3) and/or del (17p13.1). In a study of Dhodapkar et al (37) , the loss of IFN-γ production by freshly isolated iNKT cells in the course of progressive myeloma was observed. An increase in IL-4 production, in comparison to IFN-γ expression, by iNKT cells was identified in mice following immunization with α-GalCer (38, 39) . Tahir et al (21) reported decreased IFN-γ:IL-4 ratio in prostate cancer patients. IL-4 inhibits the programmed death of CLL B cells and prolongs the cell lifespan (40) . This effect was not detected for the B cells obtained from healthy subjects (4). Smyth et al (41) suggested that IL-4 is not required for mediating α-GalCer activity against cancer. The results suggest that the frequency of iNKT cells and the profile of cytokines expressed by iNKT cells does not affect B cell apoptosis in patients with CLL. The results obtained by Palmer et al (42) indicate that iNKT cells are dispensable in the development or accumulation of CD5 + B cells in mice prone to benign or leukemic CLL-like B cell expansion.
According to the literature, numerous studies have noted not only qualitative, but also quantitative changes concerning iNKT cells in the course of neoplastic diseases (21, (43) (44) (45) (46) (47) . The number of analyzed iNKT cells decreased in patients with solid tumors (21, 43, 47) and hematological malignancies, in comparison with healthy subjects (45, 46, 48) . Fais et al (49) observed a significantly lower number of iNKT cells in patients with CLL compared with HVs. The results of the present study, and of our previous study (46) , indicated a significantly lower percentage of iNKT cells in the PB of patients with CLL when compared with that of HVs. Certain prior studies have associated a reduced number of iNKT cells not with a tumor, but with a risk of tumor growth (43, 50) . Conversely, Weinkove et al (31) suggested that the absolute number of circulating iNKT cells in patients with untreated CLL is normal, and the reduction occurred in a group of patients undergoing chemotherapy. The data obtained in the current study are concordant with those recently reported by Weinkove et al (31) , who determined there was no significant association between the iNKT cell frequency and the clinical disease stage or expression of adverse prognostic markers (i.e., ZAP-70).
In the present study, flow cytometry and RT-qPCR were used to detect the levels of IL-4 and IFN-γ mRNA in iNKT cells. The level of transcription for IL-4 and IFN-γ was higher in leukemic B cells compared with HVs. Similarly, the percentage of iNKT cells expressing these molecules was higher in patients with CLL. However, the methods used in the present study were not able to indicate whether iNKT cells with IL-4 and IFN-γ expression could also secrete IL-4 and IFN-γ. Nevertheless, the pattern of IL-4 and IFN-γ expression in the cytoplasm of iNKT cells together with the expression of IL-4 and IFN-γ mRNA may suggest that iNKT cells are able to produce these cytokines. Further study is required in order to determine whether a change in the pattern of released cytokines may have an important role in the pathogenesis of CLL. It must be noted that no significant association was identified between the percentage of iNKT cells with intracellular IL-4 or IFN-γ expression and the TTT. Furthermore, no statistically significant difference was observed in the iNKT + ratio between the patients requiring therapy and the patients without treatment.
CD1d expression is crucial for the presentation of glycolipids to iNKT cells (31) . It was previously demonstrated that there is lower CD1d molecule expression in the B cells of patients with CLL, as compared with HVs (25) . Similarly, Weinkove et al (31) identified that leukemic B cells express CD1d at lower levels. The results of the current study are consistent with those of Weinkove et al (31) , who reported reduced CD1d expression on the monocytes of patients with CLL. Nevertheless, the role of CD1d in antitumor immunity is not well understood. It has been reported that iNKT cells fail to develop in CD1d -/-mice (51). Wang et al (52) identified that resting iNKT cells that had not been exposed to APC with CD1d expression did not contain detectable levels of IFN-γ mRNA. Fais et al (49) reported that CD1d on leukemic B cells was able to present α-GalCer to NKT cells, as revealed by cytokine production, cytotoxicity and proliferation assays. In the present study, no association between the expression levels of IL-4 or IFN-γ in iNKT cells and CD1d molecule expression on leukemic B lymphocytes or monocytes of patients with CLL was identified.
Numerous issues concerning the development and progression of CLL are still unclear. Over the years, numerous abnormalities concerning leukemic B lymphocytes and non-leukemic cells of the immune system that occur during the course of CLL have been characterized (53) . The functional dysfunction of NKT-like cells in terms of cytokine production have previously been demonstrated (54) . However, there are currently few publications concerning the cytokine expression profiles of iNKT cells obtained from patients with CLL (31, 49) . By producing a variety of cytokines, the iNKT lymphocytes modify the microenvironment and, therefore, may influence tumor growth (21, 55, 56 high T cells (data not presented). T regs can suppress the proliferation, cytokine secretion and cytotoxic activity of NKT cells (59) . Monitoring the number and function of iNKT cells may be important for assessing immunological dysfunction in patients with CLL. However, currently it cannot unequivocally be said that monitoring the percentage of iNKT cells or their function can provide useful information concerning the activity or progression of the disease. In the present study, only two cytokines were analyzed. They were chosen since they represent cytokines typical for Th1-and Th2-type lymphocytes with a well-known antagonizing action. Further analysis of other cytokines produced by iNKT cells, including IL-17 and TGF-β, may be important for understanding the pathogenesis of CLL.
